Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel

Author(s):  Arnold John J, Asbill Scott

Issue:  Nov/Dec 2009 - Geriatric Compounding
View All Articles in Issue

Page(s):  569-571

The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel Page 1
The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel Page 2
The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel Page 3

Download in electronic PDF format for $75

Abstract:  The purpose of this study was to evaluate the in vitro release and ex vivo penetration of baclofen following incorporation into a 2% poloxamer lecithin organogel. Franz cells were utilized for both the release and penetration studies. Semi-permeable dialysis membranes were used for the release testing, and porcine skin was used as the model skin for the penetration study. Baclofen release and penetration at predetermined time points were assessed using high-performance liquid chromatographic analysis. Results demonstrated that baclofen release from the poloxamer lecithin organogel was significantly higher than its penetration through porcine skin. The amount of baclofen released by the poloxamer lecithin organogel was linear up to 12 hours. Approximately 20% of applied drug was released over the duration of the study period. In comparison with drug released, the ex vivo penetration of baclofen through porcine skin was very low with only minute detectable quantities (significantly less than 1%) after the 12-ho

Related Keywords: John J. Arnold, PhD, Scott Asbill, PhD, baclofen, transdermal delivery, topical preparations, skin penetration, poloxamer lecithin organogel, dermal application, formulation, PLO, muscle relaxant

Related Categories: EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel
Arnold John J
, Asbill Scott
Nov/Dec 2009
Pg. 569-571

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Woodall Rachel
, Arnold John J, McKay Doug, Abill C Scott
May/Jun 2013
Pg. 247-253

In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Heustess Allie
, Asbill Scott, Eagerton David, Arnold John
Nov/Dec 2014
Pg. 512-515

Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Boddu Sai HS
, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
May/Jun 2014
Pg. 256-261

Skin Penetration and Antinociception of Topical Gabapentin Formulations
Bryson Evan
, Asbill Scott, Sweitzer Sarah
Nov/Dec 2014
Pg. 504-511

The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs
Bramwell Bethany L
, Williams LaVonn A
Jan/Feb 2012
Pg. 62-63

Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin
Le Uyen Minh
, Baltzley Sarah, AlGhananeem Abeer
Nov/Dec 2018
Pg. 498-503

Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives
Trimble John
, Light Bob
May/Jun 2016
Pg. 250-256

Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji
, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2022
Pg. 65-71

Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time
Heustess Allie
, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott
Mar/Apr 2015
Pg. 167-173

Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations
Bryson Evan
, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott
Mar/Apr 2015
Pg. 161-166

Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date
Pignato Alyssa
, Pankaskie Marvin, Birnie Christine
Nov/Dec 2010
Pg. 522-525

Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Glisson James K
, Wood Rebecca L, Kyle Patrick B, Cleary John D
May/Jun 2005
Pg. 242-246

Baclofen 5%, Capcaicin 0.075%, Ketoprofen 10%, and Tetracaine 2% in Pluronic Lecithin Organogel
Allen Loyd V Jr
Nov/Dec 2010
Pg. 513

Baclofen 5%, Gabapentin 5%, Ketoprofen 10%, and Lidocaine 5% in Pluronic Lecithin Organogel
Allen Loyd V Jr
Nov/Dec 2010
Pg. 514

Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
Nov/Dec 2010
Pg. 512

Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives
Trimble John O
, Light Bob
Nov/Dec 2017
Pg. 530-535

Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James
, Ramsay Dale, Das Nandita G, Das Sudip K
Mar/Apr 2004
Pg. 101-105

Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application
Polonini Hudson
, de Oliveira Ferreira Anderson, Dijkers Eli
Sep/Oct 2021
Pg. 422-426

Return to Top